ArriVent BioPharma Receives FDA Clearance for ARR-002 IND
ArriVent BioPharma announced clearance of an investigational new drug application by the FDA for ARR-002, a MUC16/NaPi2b targeting tetravalent antibody-drug conjugate with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.
